头颈部鳞状细胞癌中CB1和CB2单克隆抗体质量与一致性的评估
本研究利用5例头颈癌患者的组织和细胞系,通过蛋白质印迹、免疫组化和免疫荧光比较CB1/CB2抗体表现,并对8例大麻使用者和10例对照的FFPE切片行免疫组化亚组分析。结果显示不同方法间抗体结果不一致,作者建议谨慎解读并采用多种实验方法交叉验证。
要点
- 5例患者中CB1在WB和IF均阳性而IHC阴性,方法间结果不一致。
- 部分样本CB2经WB阳性,但IF和IHC均未成功检出。
- 亚组免疫组化中CB1阳性者为8例使用者中1例、10例非使用者中3例。
核心结论
- 作者认为CB1/CB2抗体数据的解读应谨慎,并推荐通过多种实验方法确认结果。
研究设计与样本
- 研究使用5例头颈癌患者的组织生成细胞系和福尔马林固定石蜡包埋切片,行蛋白质印迹、免疫组化和免疫荧光分析。
- 对8例大麻使用者和10例对照的福尔马林固定石蜡包埋切片行免疫组化亚组分析,并比较各方法结果的一致性。
主要发现
- 在所有患者中,蛋白质印迹和免疫荧光均为CB1阳性,而免疫组化为阴性。
- 部分样本经蛋白质印迹为CB2阳性,但免疫荧光和免疫组化检测均未成功。
- 亚组分析中,大麻使用者8例中1例、非使用者10例中3例为CB1阳性。
临床怎么用
- 作者建议谨慎解读CB1/CB2抗体数据,并通过多种实验方法确认结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Marijuana has numerous roles as an agonist in the endocannabinoid signaling system (ESS). This study evaluated monoclonal antibodies across experimental techniques to establish a framework for studying ESS receptors, CB1 and CB2. METHODS: Tissue from five patients with head and neck cancer were used to generate cell lines and formalin-fixed paraffin-embedded (FFPE) sections, which were analyzed by western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Subgroup analysis was performed on FFPE sections from 8 marijuana users and 10 controls by IHC. Results were compared across methods for consistency. RESULTS: In all patients, WB and IF were CB1 positive, whereas IHC was negative. Select samples were CB2 positive by WB, but failed IF and IHC applications. In subgroup analysis, 1 of 8 users and 3 of 10 nonusers were CB1 positive. CONCLUSIONS: Interpretation of CB1/CB2 antibody data should be performed cautiously and confirmation of findings across multiple experimental methods is recommended.
引用
- Daniels KE, Luginbuhl AJ, Mardekian SK, et al. Assessment of quality and consistency of monoclonal antibodies for CB1 and CB2 in head and neck squamous cell carcinoma. Head Neck. 2019. PMID: 31037797. doi:10.1002/hed.25794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。